Drug
Montanide ISA 51
Montanide ISA 51 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
NCT04013672
terminatedphase_2
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
NCT00184067
completedphase_2
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00059475
completedphase_2
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
NCT00080353
Clinical Trials (4)
Showing 4 of 4 trials
NCT04013672Phase 2
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
NCT00184067Phase 2
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
NCT00059475Phase 2
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00080353Phase 2
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4